Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy

Hsu, Jen-YuJen-YuHsuHSIN-YUN SUNHsieh, Tan-WenTan-WenHsiehSUI-YUAN CHANGYU-CHUNG CHUANGYU-SHAN HUANGHsiao, Ching-YuChing-YuHsiaoSu, Yi-ChingYi-ChingSuLiu, Wen-ChunWen-ChunLiuChang, Shu-FangShu-FangChangCHIEN-CHING HUNG2022-05-122022-05-122022-02-1322137165https://scholars.lib.ntu.edu.tw/handle/123456789/610515We aimed to investigate the incidence of low-level viremia (LLV) and its impact on virologic failure (VF) in people living with HIV (PLWH) on stable antiretroviral therapy (ART) who switched to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (EVG/c/FTC/TAF).enIntegrase strand transfer inhibitor; Plasma HIV RNA load; Resistance-associated mutation; Viral blip; Virologic response[SDGs]SDG3Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapyjournal article10.1016/j.jgar.2022.02.007351722012-s2.0-85126042953https://scholars.lib.ntu.edu.tw/handle/123456789/604293